


Innovation in Plasma Protein Purification

Improving manufacturing processes ... increasing the yield of Plasma Proteins

ProMetic and the American Red Cross have jointly utilized their respective technologies and expertise to develop an improved manufacturing technology providing enhanced yield and purity of blood plasma derived products compared to industry standards. Expertise has been consolidated within ProMetic Life Sciences through ProMetic BioTherapeutics, Inc. (PBT). The core technology, an innovative Plasma Protein Purification System™ (PPPS™) is a combination of individually proven steps, but presented in a unique and optimized sequence. The plasma industry largely use the Cohn precipitation techniques developed during the 2nd World War to primarily recover Albumin from plasma for use in hypovolemic shock. The net recovery of other valuable plasma proteins e.g. Factor VIII (for Hemophilia A), IgG (for Primary Immune Deficiencies) or Alpha1-antitrypsin (for Hereditary Emphysema) remain relatively poor at approximately 20%, 50% and from 15%, respectively.



Yield and Revenue Benefits

Yield benefit		Net yields			Revenue per liter (US\$)		
Products	Units/Liter	Cohn	PPPS™*	% improvement	US wholesale ASP**	Cohn	PPPS™
IGIV	Grams	4.00	5.50	33%	67.00	268	369
A1PI	Grams	0.20	0.90	375%	250	50	238
vWF/FVIII	Intl. Units	200	450	125%	0.70	140	315
* Actual yields through intermediate, with estimates to final yields						458	922
** ASP = Average selling price						Increased revenue per litre 110%	

Applications of PBT Process Technology

PPPS™ - Implementation of the whole fractionation process to form the backbone of new plasma fractionation facilities, which allow for the recovery of the proteins directly from plasma, further improving the extraction yield by up to 80%, and increasing potential revenues.


Hyperimmunes - Increase yield of hyper immunes recovered from plasma of donors who have high levels of specific immunoglobulins to the “pathogen” or antigen to which they have been exposed by infection or vaccination (e.g. Hyperimmunes for Hepatitis B, Hepatitis C, cytomegalovirus, rabies etc.)

Orphan drugs - Recovery of certain proteins which have established therapeutic value, but cannot be extracted effectively via current manufacturing practices, or that are not the focus of large plasma fractionators.

Using Core Technologies

The use of technology and the alliance with the American Red Cross exemplifies the many ways in which ProMetic leverages its technology and competence

Affinity chromatography




Capture Wash Recover

PBT's PPPS™ process is an application of ProMetic's Core Technology to extract the most valuable therapeutic proteins from recovered and source plasma. Each protein is removed from the plasma by a specific ProMetic Mimetic Ligand™ adsorbent and subsequently purified in a side stream. The removal sequence has been optimized to give exceptionally high protein recoveries at unprecedented activity levels and will allow the recovery of new biotherapeutics as they are discovered and identified. The effect of this process will be to reduce the significant losses incurred using the more conventional Cohn precipitation process.

Markets

The protein plasma-derived industry (excluding recombinant proteins, ca. \$2.4 Billion) represents a current market with annual sales of over US \$6 Billion. The CAGR is estimated at 6% in the range 5-8% pa. IGIV accounts for 50% of US fractionation revenues, US demand for IGIV is currently 50% of the global market and new indications for this protein could double the market. Key markets that do not yet have their own plasma fractionation facilities include Canada, Latin America, the Middle-East, India, Africa and several East European and Far Eastern countries. Eighty percent of haemophiliacs in the world do not receive appropriate treatment, either because of insufficient supply or because they cannot afford the products. In the coming years, the plasma fractionation industry will be confronted with the major challenge of increasing the output and further enhancing the safety of plasma-derived products.



The future of this industry lies in its ability:

- to build new facilities,
- to access to technology capable of improving yield and
- the development of new therapeutics (Plasma proteomics)

Many developed countries have experienced shortages of plasma-derived products, mostly owing to an increasing in clinical demand.

Competitive Position/Strategy

Poised to Help Fill Global Demand for Plasma Proteins

Plasma fractionation is by far the largest global therapeutic protein industry. The vast majority of players in the plasma industry still rely on the traditional Cohn process, developed from the 1940's onwards, to recover valuable proteins from plasma. This process, however, is significantly insufficient to meet worldwide demand. ProMetic is proud to have pooled all the essential elements together to revolutionize the plasma fractionation industry and to offer the next generation of plasma-derived therapeutics.

The future of foundations of this industry are in to access to new technology ensuring improved yields of safe products and the ability to develop new and novel therapeutics. ProMetic and its new extraction technology is a world first; creating a significant worldwide business opportunity.

ProMetic has negotiated agreements for the use of this technology with Kedrion S.p.A. in Italy, Wuhan Institute for Biological Products (WIBP) in China and Blue Blood in Taiwan. Following a strategic alliance announced earlier on between ProMetic and Sartorius Stedim Biotech, Sartorius is the preferred supplier and technology provider of filtration equipment and consumables for WIBP and Blue Blood.



PROMETIC

ProMetic BioTherapeutics, Inc.

a wholly owned subsidiary of
ProMetic Life Sciences Inc.
(TSX:PLI) www.prometic.com

Patent Protection

Patents are pending
at the international level

Contact

For further information regarding the
technology please contact:

Pierre Laurin
CEO
ProMetic BioTherapeutics, Inc.

Tel: +1 (514) 341-2115
p.laurin@prometic.com